Business Context and Reporting Period
Company: Techne Corporation (now BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1995 (First Quarter of Fiscal 1996)
Operations: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. R&D Systems comprises Biotechnology and Hematology divisions, manufacturing cytokines, antibodies, assay kits, and hematology controls. R&D Europe distributes these products in Europe and develops its own biotechnology lines.
Key Financial Metrics
| Metric | Q1 FY1996 (Ended 9/30/95) | Q1 FY1995 (Ended 9/30/94) |
|---|---|---|
| Net Sales | $12,794,298 | $10,960,794 |
| Gross Margin | $8,130,401 (63.5%) | $6,505,497 (59.4%) |
| Net Earnings | $1,785,282 | $1,437,981 |
| Earnings Per Share (Diluted) | $0.18 | $0.15 |
| Cash & Cash Equivalents | $5,984,732 | $5,983,644 |
| Short-term Investments | $8,805,790 | $10,627,730 |
| Total Current Assets | $27,431,190 | $27,805,919 |
| Total Current Liabilities | $4,684,827 | $4,118,980 |
| Net Cash from Operating Activities | $2,089,542 | $1,867,130 |
| Capital Additions (Investing) | ($3,043,257) | ($172,449) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($1.83M) year-over-year. Growth was driven by a 13% increase in R&D Systems sales and a 29% increase in R&D Europe sales.
- Product Drivers: Approximately 49% of the sales increase was attributed to R&D Systems' immunoassay (Quantikine) kits. The Hematology Division also contributed 12% to the increase after reacquiring proficiency survey business lost in the prior year.
- Margin Expansion: Gross margin percentage improved from 59.4% to 63.5%. R&D Europe margins rose from 45.6% to 51.6% due to a shift toward higher-margin in-house products. Hematology margins increased from 33.4% to 39.4%.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 27% ($655k), largely due to the opening of a new sales subsidiary in Germany and increased staffing. R&D expenses increased 26% ($516k) to support new product lines.
- Capital Expenditures: Significant increase in capital additions to $3.04M, primarily for leasehold improvements ($2.47M) at the 2201 Kennedy building for the Biotechnology Division.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects similar revenues in the second quarter of fiscal 1996 due to seasonal slowing during the holiday period. Revenues are projected to accelerate to record levels in the second half of fiscal 1996 following new product releases and the post-holiday season.
- Liquidity: The Company holds $14.79M in cash and short-term investments. It maintains an unsecured line of credit of $750,000 at the prime rate. Management believes current funds and operating cash flow are sufficient to meet future requirements.
- Tax Rate: The effective tax rate increased to approximately 32% from 30% in the prior year due to the expiration of the U.S. credit for research and development expenditures.
- Capital Needs: Approximately $3.4M in additional capital expenditures are planned for the remainder of fiscal 1996, to be financed by existing cash and investment maturities.
- Dividends: The Company has never paid dividends and has no plans to do so in fiscal 1996.
Investor Verification Checklist
- Seasonality Impact: Verify if Q2 revenue aligns with management's expectation of a seasonal slowdown.
- Capital Expenditure Utilization: Confirm the occupancy timeline and cost efficiency of the new 2201 Kennedy building leasehold improvements.
- Product Mix Sustainability: Assess whether the improved gross margins in R&D Europe and Hematology are sustainable or driven by one-time product mix shifts.
- Foreign Exchange Exposure: Monitor the impact of currency fluctuations on R&D Europe's results, noting the prior year's exchange gain vs. current year's minimal loss.
- Debt Covenants: Review the terms of the $750,000 unsecured line of credit to ensure no covenants are at risk given the increased capital spending.